Ratings by BofA Securities (Jason M. Gerberry)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/30/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2026 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2026 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 4/15/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/8/2025 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2024 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Buy (N/A) |
15.86 (31.49) |
98.55% | Details | |
| 8/3/2023 | Allogene | ALLO | Maintain | Underperform (N/A) |
|
Details | ||
| 1/5/2023 | Allogene | ALLO | Maintain | Underperform (N/A) |
|
Details | ||
| 1/5/2023 | Applied Molecular Transport | AMTI | Downgrade | Underperform (Buy) |
0.48 (0.26) |
-45.83% | Details | |
| 12/12/2022 | Allogene | ALLO | Downgrade | Underperform (Buy) |
8.76 (2.09) |
-76.14% | Details | |
| 7/7/2022 | Applied Molecular Transport | AMTI | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2021 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2020 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details |
